Cancer cure now possible? Major breakthrough Treatment with Dostarlimab

A cancer patient has new hope for a cancer cure now. Let us look into details to beat cancer with the new drug Dostarlimab.

When we talk about cancer, the first thing that comes to our mind is the word, “deadly” Research is advanced now and with new advancements in medical science, the cure is now possible for cancer too. As per reports, cancer is the leading cause of death accounting for nearly 10 - 15 million deaths in 2021. As per WHO, one in 6 deaths is caused by cancer. 

Here is some good news for people battling cancer and hoping to defeat cancer in their life. With advanced drug therapies, many clinical trials and research are being done to find a drug that can help beat cancer. 

Researchers have designed such a drug, which has the power to eliminate this cancer up to 100 percent. 

A New Hope for Cancer Cure

New miracles happen every day in the field of science and recently researchers have made a big achievement. Yes, researchers have made a big achievement in the fight against rectal cancer because they have developed a new drug, which has been found to be 100% effective in the treatment of this disease. Dostarlimab is a medicine that has come to light with its therapeutic effective properties against cancer. 

The clinical trial  is successful in 18 patients

In a clinical trial, a drug named Dostarlimab was tested on 18 patients for about 6 months, and when this trial ended, it was found that the tumor was cured. This was done in the USA, as reported by the New York Times. 

These 18 patients have undergone various treatments before cancer including chemotherapy, radiation, and invasive therapy. Patients who reported having undergone these trials reported that they required no other treatment or therapy for cancer and their cancer was cured. 

The solution to Cancer- Major breakthrough in the history of cancer

As per Dr. Luis. A. Diaz J of New York’s Memorial Sloan Kettering Cancer Center said that- “ The first time in history this has ever happened.” As per reports, the patient took the drug, Dostarlimab every three weeks for six months during the trial. Notably, all the cases were in the same stage of cancer and there was no further metastasis reported. 

During the study, doctors also conducted a series of follow-up tests including a physical examination of the patients, MRI scans, and PET scans. The study was carried out by the pharmaceutical company GlaxoSmithKline. The study was published on June 6 in the New England Journal of Medicine.

What is Dostarlimab?

Dostarlimab is a drug in which the molecules are made by the lab and they work as a substitute for antibodies in the human body against cancer

What next?

Let us check whether these 18 patients can now pass through a second trial lab for the next step. According to experts, this is shocking and unbelievable. 

Let us hope for a better future for cancer patients with advanced recovery and new clinical trails 

Tags : #cancercure #cancerdrug #cancerpatients #cancertherapy #research #clinicaltrail #Dostarlimab #smitakumar #medicircle

About the Author

Dr. Rati Parwani

Dr Rati Parwani is a Practising Professional BHMS Doctor having experience of 8 years in the medical field. Her approach towards each and every patient is the utmost professional with high standards of practice. She has nurtured her writing skills and proves it as an asset to her professionalism. She has experience in content writing and likes her writing ethical and scientific-based.

Related Stories

Loading Please wait...


Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023